Innealta Capital’s Regenxbio RGNX Stock Holding History

Innealta Capital’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-8	Closed	-$94	–	1338
2024 Q2	$94	Buy	+8	New	+$125	﹤0.01%	1693

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Innealta Capital's RGNX Position: Q3 2024 in Review

Innealta Capital sold out of Regenxbio (RGNX) in Q3 2024, closing a stake of 8 shares — an estimated $94 sold.

Innealta Capital first reported a position in RGNX in Q2 2024 and held it in 1 quarter. The position peaked at $94 in Q2 2024. 186 funds tracked by Wall St. Rank hold RGNX as of Q3 2024.

Innealta Capital reported no remaining Regenxbio position as of Q3 2024 after selling out during the quarter.
Innealta Capital sold 8 Regenxbio shares in Q3 2024, an estimated $94.
Innealta Capital first reported a position in Regenxbio in Q2 2024 and held it in 1 quarter.
Innealta Capital's Regenxbio position peaked at $94 in Q2 2024.
186 funds tracked by Wall St. Rank held Regenxbio as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.